telmisartan has been researched along with dipyridamole in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Diener, HC; Sacco, R; Yusuf, S | 2 |
| Diener, HC | 1 |
| Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S | 2 |
| Kent, DM; Thaler, DE | 1 |
| Kappelle, LJ | 1 |
| Lees, KR | 1 |
| Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S | 1 |
| Blatchford, J; Demchuk, AM; Diehl, A; Diener, HC; Forsting, M; Gizewski, ER; Hermansson, K; Möller-Hartmann, C; Sacco, RL; Saver, JL; Wanke, I; Warach, S; Weber, R; Weimar, C | 1 |
| Kamal, AK; Wadiwala, MF | 1 |
3 review(s) available for telmisartan and dipyridamole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
The PRoFESS trial: future impact on secondary stroke prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Forecasting; Humans; Internationality; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Treatment Outcome; Vasodilator Agents | 2007 |
5 trial(s) available for telmisartan and dipyridamole
| Article | Year |
|---|---|
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Combinations; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Research Design; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Treatment Outcome | 2007 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Vascular Diseases | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cognition; Dipyridamole; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; International Cooperation; Male; Mental Status Schedule; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Severity of Illness Index; Stroke; Telmisartan; Ticlopidine | 2008 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Cerebral Infarction; Clopidogrel; Dipyridamole; Female; Humans; Intracranial Embolism; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Socioeconomic Factors; Stroke; Telmisartan; Ticlopidine; Tomography, X-Ray Computed; Treatment Outcome; Vasodilator Agents | 2012 |
What is better antiplatelet agent to prevent recurrent stroke?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Evidence-Based Medicine; Humans; Male; Middle Aged; Patient Compliance; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Treatment Outcome | 2012 |
14 other study(ies) available for telmisartan and dipyridamole
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Humans; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Telmisartan; Ticlopidine | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Controlled Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Placebos; Platelet Aggregation Inhibitors; Recurrence; Risk; Stroke; Telmisartan; Ticlopidine; Time Factors | 2003 |
Correction to the PRoFESS Trial paper by Diener et al. (Cerebrovasc Dis 2007;23:368-80.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Data Interpretation, Statistical; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Telmisartan; Ticlopidine | 2008 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine | 2008 |
[Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Headache; Humans; Platelet Aggregation Inhibitors; Stroke; Telmisartan; Ticlopidine | 2008 |
PRoFESS.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Telmisartan; Ticlopidine; Treatment Outcome | 2009 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; Brain Ischemia; Clopidogrel; Diastole; Dipyridamole; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Reference Values; Risk; Stroke; Systole; Telmisartan; Ticlopidine; Vascular Diseases | 2011 |